Ongoing studies on novel agents and combinations of common nodal PTCLs
| Drug . | Mechanism . | Phase . | Patient population . | Clinicaltrials.gov identifier . |
|---|---|---|---|---|
| Targeted therapy | ||||
| KT-33335 | STAT3 degrader | 1a/1b | Rel/ref PTCL | NCT05225584 |
| Linperlisib36 | PI3Kδ Inhibitor | 2 | Rel/ref PTCL | NCT05274997 |
| CPI-81837 | ITK inhibitor | 1/1b | Rel/ref PTCL | NCT03952078 |
| Immune-based strategies | ||||
| Lacutamab38 | anti-KIR3DL2 antibody | 2 | Rel/ref PTCL | NCT04984837 |
| DR-0139 | anti-CD94 antibody | 1/2 | Cytotoxic lymphomas | NCT05475925 |
| ONO-468540 | PD1/CD3 biospecific antibody | 1 | Rel/ref PTCL and CTCL | NCT05079282 |
| CTX13041 | CD70 CAR-T | 1 | Rel/ref PTCL and CTCL | NCT04502446 |
| CD5CAR-T42 | CD5 CAR-T | 1 | T-cell malignancies | NCT04594135 |
| CAR-37 T cells43 | CD37 CAR-T | 1 | CD37+ malignancies | NCT04136275 |
| Anti-CD7 CAR-T44 | CD7 CAR-T | 1 | CD7+ T-cell lymphomas | NCT04823091 |
| AUTO445 | TRBC1 CAR-T | 1/2 | T-cell malignancies | NCT03590574 |
| Pembrolizumab plus decitabine and pralatrexate | PD-1 blockade, epigenetic modification | 1 | Rel/ref PTCL and CTCL | NCT03240211 |
| Durvalumab plus pralatrexate, azacytidine, or romidepsin | PDL-1 plus various | 1/2 | Rel/ref PTCL | NCT03161223 |
| AFM13 plus AB101 | CD30/CD16a biospecific plus NK cells | 1 | Rel/ref CD30+ PTCL | NCT05883449 |
| Novel combinations | ||||
| Romidepsin plus azacytidine vs investigator’s choice | Epigenetic modification | 2 randomized | Rel/ref PTCL | NCT04747236 |
| Chidamide plus duvelisib | HDACi plus PI3K-δ,γ inhibitor | 2 | Untreated PTCL | NCT05976997 |
| Chidamide plus azacitdine | Epigenetic modification | 2 | Untreated PTCL unfit for conventional chemotherapy | NCT04480125 |
| Duvelisib plus ruxolitinib | PI3K and JAK1/2 | 1b | Rel/ref PTCL and CTCL | NCT05010005 |
| Drug . | Mechanism . | Phase . | Patient population . | Clinicaltrials.gov identifier . |
|---|---|---|---|---|
| Targeted therapy | ||||
| KT-33335 | STAT3 degrader | 1a/1b | Rel/ref PTCL | NCT05225584 |
| Linperlisib36 | PI3Kδ Inhibitor | 2 | Rel/ref PTCL | NCT05274997 |
| CPI-81837 | ITK inhibitor | 1/1b | Rel/ref PTCL | NCT03952078 |
| Immune-based strategies | ||||
| Lacutamab38 | anti-KIR3DL2 antibody | 2 | Rel/ref PTCL | NCT04984837 |
| DR-0139 | anti-CD94 antibody | 1/2 | Cytotoxic lymphomas | NCT05475925 |
| ONO-468540 | PD1/CD3 biospecific antibody | 1 | Rel/ref PTCL and CTCL | NCT05079282 |
| CTX13041 | CD70 CAR-T | 1 | Rel/ref PTCL and CTCL | NCT04502446 |
| CD5CAR-T42 | CD5 CAR-T | 1 | T-cell malignancies | NCT04594135 |
| CAR-37 T cells43 | CD37 CAR-T | 1 | CD37+ malignancies | NCT04136275 |
| Anti-CD7 CAR-T44 | CD7 CAR-T | 1 | CD7+ T-cell lymphomas | NCT04823091 |
| AUTO445 | TRBC1 CAR-T | 1/2 | T-cell malignancies | NCT03590574 |
| Pembrolizumab plus decitabine and pralatrexate | PD-1 blockade, epigenetic modification | 1 | Rel/ref PTCL and CTCL | NCT03240211 |
| Durvalumab plus pralatrexate, azacytidine, or romidepsin | PDL-1 plus various | 1/2 | Rel/ref PTCL | NCT03161223 |
| AFM13 plus AB101 | CD30/CD16a biospecific plus NK cells | 1 | Rel/ref CD30+ PTCL | NCT05883449 |
| Novel combinations | ||||
| Romidepsin plus azacytidine vs investigator’s choice | Epigenetic modification | 2 randomized | Rel/ref PTCL | NCT04747236 |
| Chidamide plus duvelisib | HDACi plus PI3K-δ,γ inhibitor | 2 | Untreated PTCL | NCT05976997 |
| Chidamide plus azacitdine | Epigenetic modification | 2 | Untreated PTCL unfit for conventional chemotherapy | NCT04480125 |
| Duvelisib plus ruxolitinib | PI3K and JAK1/2 | 1b | Rel/ref PTCL and CTCL | NCT05010005 |
CTCL, cutaneous T-cell lymphoma; ITK, IL2-inducible T-cell kinase; NK, natural killer; PD1, programmed death 1; PDL-1, programmed death ligand 1; Rel/ref, relapsed/refractory; STAT, signal transducer and activator of transcription; TRBC1, T-cell receptor beta constant 1.